Clinical Trials

We have multiple ongoing clinical trials. Sponsors for these include the StrokeNet program, the National Institutes of Health (NIH), as well as pharmaceutical trials. Many clinical trials can be categorized by the time point surrounding a stroke that is studied. A list of ongoing trials is as follows:

  1. Hyperacute: Stroke has occurred within the last six hours:
    1. MOST: Multi-arm Optimization of Stroke Thrombolysis: a Single Blinded, Randomized Controlled Adaptive, Multi-arm, Adjunctive-thrombolysis Efficacy Trial in Ischemic Stroke
    2. TIMELESS: A Phase III, Prospective, Double-blind, Randomized, Placebo-controlled Trial of Thrombolysis in Imaging-eligible, Late-window Patients to Assess the Efficacy and Safety of Tenecteplase
    3. FASTEST: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time
  2. Acute: Stroke has occurred within the last 48 hours:
    1. CHARM: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
    2. BMS-CV010-031-Axiomatic: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
    3. ENRICH: A Multi-center, Randomized, Clinical Trial Comparing Standard Medical Management to Early Surgical Hematoma Evacuation Using Minimally Invasive Parafascicular Surgery (MIPS) in the Treatment of Intracerebral Hemorrhage (ICH).
    4. EAISE: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
  3. Subacute: Stroke has occurred from 48 hours up to about six months ago:
    1. ARCADIA: AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
    2. SleepSMART: Sleep for Stroke Management and Recovery Trial
    3. SATURN: Statins Use In Intracerebral Hemorrhage Patients
  4. Chronic: Stroke has occurred in the last 6-12 months:
    1. Carotid Occlusion-MROEF
    2. PFO Amplatzer prevention/intervention
    3. Crizanlizumab RVCS-S
    4. SCD MRI
    5. PAM SCD
    6. ASPIRE: Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
    7. ARCADIA CSI: ARCADIA CSI (Cognition and Silent Infarcts)
    8. WWISH
    9. I-AQUIRE: Perinatal Arterial Stroke: A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)

Contact Jill Newgent at 314-747-5552 or 314-747-3795 if you have questions related to your ongoing participation in one of our clinical trials.

For more information related to all registered publicly and privately funded clinical studies, please visit the U.S. National Library of Medicine database.